All About Cardiovascular System and Disorders

DECEMBER 15, 2023

CLEAR Trial of Bempedoic Acid Bempedoic acid is an ATP citrate lyase inhibitor, acting upstream of HMGCoA reductase targeted by statins, and reduces LDL cholesterol levels. CLEAR trial had patients for both primary and secondary prevention of cardiovascular disease. Median follow up was for 40.6 There was 29.2

Cholesterol 52

Cholesterol Myocardial Infarction Cardiovascular Disease Diabetes 52

Dr. Paddy Barrett

AUGUST 22, 2023

However Most people do not appreciate that being a carrier of APOE4 significantly increases the risk of cardiovascular disease also. APO E is also centrally involved in cholesterol metabolism. APO E is also centrally involved in cholesterol metabolism. i.e. LDL-Cholesterol/APOB goes down. Here’s how.

Cholesterol 52

Cholesterol Dementia Cardiovascular Disease Coronary Artery Disease 52

Dr. Paddy Barrett

SEPTEMBER 19, 2023

I do apologise for being direct, but this issue is one of the most frequent barriers I encounter to initiating cholesterol-lowering therapy. At the exact same time, cholesterol concentrations are also at their lowest. At the exact same time, cholesterol concentrations are also at their lowest. Let’s break this down.

Dementia 52

Dementia Cholesterol Biomarkers Circulation 52

Circulation: Cardiovascular Quality & Outcomes

OCTOBER 20, 2023

BACKGROUND:The relationship between marijuana use and cardiovascular health remains uncertain, with several observational studies suggesting a potential association with increased adverse atherosclerotic cardiovascular disease (ASCVD) outcomes. mg/dL,P=0.53), total cholesterol (191.2 female; 13% non-Hispanic Black), 26.6%

Risk Factors 40

Risk Factors Cardiovascular Disease Cholesterol Biomarkers 40

Journal of the American Heart Association

NOVEMBER 23, 2023

BackgroundPatients with nonalcoholic fatty liver disease are at increased risk to develop atherosclerotic cardiovascular diseases. The expression of GPBAR1 in the human endothelium correlated with the expression of inflammatory biomarkers. Journal of the American Heart Association, Volume 12, Issue 23 , December 5, 2023.

Aortic 40

Aortic Aneurysm Plaque Cholesterol 40

Stroke Journal

FEBRUARY 1, 2024

It is currently unknown if these associations are confounded by pleiotropic effects of the instrumental variables (IV) on cardiovascular disease (CVD) risk factors, such as low-density lipoprotein cholesterol (LDL), diastolic blood pressure (DBP), and body mass index (BMI).

BMI 40

BMI Risk Factors Stroke Strokes 40

Dr. Paddy Barrett

OCTOBER 31, 2023

In my experience, some patients present later in life with a significantly elevated Lp(a) but have no evidence of coronary artery disease. They have the biomarker of risk but no evidence of the disease , even later in life when you would expect them to have it. This is the case with an elevated Lp(a). Atherosclerosis.

Coronary Artery Disease 52

Coronary Artery Disease Heart Disease Atherosclerosis Cardiovascular Disease 52

DAIC

JANUARY 30, 2024

Clinicians currently use two separate risk models to assess patients’ chances of having heart attacks , strokes , and other major cardiovascular events. Clinicians currently use two separate risk models to assess patients’ chances of having heart attacks , strokes , and other major cardiovascular events.

Cardiovascular Disease 52

Cardiovascular Disease Research Heart Attack Heart attacks 52

Dr. Paddy Barrett

APRIL 26, 2024

Coronary artery disease is caused by the retention of a cholesterol particle in the artery wall. But if a retained cholesterol particle is the spark. Insulin resistance and diabetes may not ‘ cause ’ coronary artery disease, but they are huge accelerants. This is the spark that sets the fire.

Heart Disease 85

Heart Disease Coronary Artery Disease Diabetes Genetic predisposition 85